Mirror Biologics and Immunovative Therapies announce publication of the technical rationale for development of a universal anti-viral vaccine targeted to protect eldery adults from COVID-19 and any future novel virus outbreaks.

Mirror Biologics, Inc. (“MBI”), the commercial development arm of Israel-based Immunovative Therapies, Ltd. (“ITL”) together with the Hadassah-Hebrew University Medical Center’s Center for Immunotherapy and Immunobiology Research today announce the publication of a...